---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-24-000027"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:57:08.561106+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zymeworks Q1 net loss $31.7M, revenue $10M; cash $420.5M, runway into 2H27

## Summary
- Revenue fell to $10.0M from $35.6M YoY due to transfer of zanidatamab responsibilities to Jazz.
- Net loss widened to $31.7M vs $24.4M in Q1 2023; R&D expense decreased 30% to $32.0M.
- Cash resources $420.5M; combined with anticipated milestones, funded into 2H 2027.
- Partner Jazz completed rolling BLA submission to FDA for zanidatamab in BTC; Phase 3 breast cancer trial planned H2 2024.
- On track for two IND submissions in 2024 for ZW191 and ZW171; Dr. Neil Gallagher joined board.

## SEC filing metadata
- accession: 0001937653-24-000027
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765324000027/0001937653-24-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765324000027/zyme-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-24-000027
- JSON: https://secwatch.observer/filing/0001937653-24-000027.json
- Plain text: https://secwatch.observer/filing/0001937653-24-000027.txt

## Key facts
- Earnings Releases
  Zymeworks Inc. reported three months ended March 31, 2024 results: revenue $10.0 million.
  - Period: three months ended March 31, 2024
  - Revenue: $10.0 million
  - Result: reported results
  source text: Revenue was $10.0 million for the three months ended March 31, 2024 compared to $35.6 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000193765324000027/0001937653-24-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.